Portfolio company SiteOne Therapeutics acquired by Eli Lilly for $1 billion.
SiteOne Therapeutics is a biopharmaceutical company advancing a novel class of highly selective small molecule inhibitors targeting NaV1
SiteOne Therapeutics is a biopharmaceutical company advancing a novel class of highly selective small molecule inhibitors targeting NaV1.7, NaV1.8, and other voltage-gated ion channels to treat sensory hyperexcitability disorders such as chronic cough, itch, and pain. The company is dedicated to the development of safe and effective pain therapeutics without the significant addiction potential and side effects of opioids.